Approaches to overcome antigen loss include designing CAR constructs that target multiple antigens, such as CD19 and CD22 for ALL (Acute Lymphoblastic Leukemia) (NCT03241940 and NCT03289455), ALL and diffuse large B cell lymphoma (DLBCL) (NCT03233854), ALL and non-Hodgkin lymphoma (NHL) (NCT03330691 and NCT03448393), and NHL and CLL (NCT03019055). Here, CD19 is linked to diffuse large B-cell lymphoma.